glp 1 agonists with cardiovascular benefit Bridging the gap between GLP1-receptor and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Cardiovascular Protective Properties of GLP-1
Description
Diaz-Trastoy O, Villar-Taibo R, Sifontes-Dubon M, Mozo-Penalver H, Bernabeu-Moron I, Cabezas-Agricola JM, et al
Individuals who stopped using GLP-1RAs were categorized into interruption and discontinuation groups
Sci Rep 9 , 8447 (2019)
[16] These receptors, when activated by allulose, may trigger signalling cascades that promote incretin hormone release, though the magnitude and clinical significance of this effect in humans requires further investigation
[DOI] [Google Scholar] 70.Thomson S
